SAM #75N98026Q00510

NIH NINDS seeks Bio-Techne Ella Immunoassay System for neuroimmunology research

This opportunity is for the acquisition of an advanced immunoassay system to support NIH neuroimmunology research. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS) - Translational Neuroradiology Section - OEM Highlight: - Bio-Techne is the Original Equipment Manufacturer (OEM) of the Ella Immunoassay System - Vendors Mentioned: - Bio-Techne - Products Requested: - Ella Automated Immunoassay System (Catalog #600-100) - Quantity: 1 - Includes: all-in-one desktop computer, Windows OS, Simple Plex software, verification cartridge, one-year warranty - Notable Requirements: - System must enable high-throughput, high-sensitivity multiplexed protein analysis for serum and plasma samples - Essential for reproducible quantification of biomarkers (e.g., neurofilament light chain [NfL], glial fibrillary acidic protein [GFAP]) - Delivery required within 30 days of order - One-year warranty included - No additional services or recurring subscriptions requested

Description

The Translational Neuroradiology Section (TNS) of the National Institute of Neurological Disorders and Stroke (NINDS) is focused on elucidating the mechanisms by which multiple sclerosis (MS) and related neuroinflammatory pathologies impact the central nervous system (CNS). Given the multifactorial nature of these diseases, high-throughput, high-sensitivity technologies are essential for comprehensive immune profiling and biomarker quantification. The Ella Immunoassay System (Bio-Techne) offers an unparalleled solution for multiplexed, protein-based analysis of serum and plasma samples, with minimal sample volume requirements and superior analytical precision. 

Specifically, the Ella enables reproducible quantification of biomarkers such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), which are critical indicators of axonal damage and astrocyte activation, respectively. Collaborating researchers have consistently cited Ella’s rapid turnaround, high sensitivity, and platform stability as key factors supporting its use in translational neuroimmunology studies. Acquisition or continued access to this system is essential to support our ongoing investigations and to maintain the rigor and reproducibility necessary for high-impact CNS researc

View original listing